Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Pentagamavunone-1 and its derivative, Chemoprevention Curcumin Analog-1.1, modulate PD-L1 and CD80 expression in breast cancer stem cells

Indonesian Journal of Biotechnology · Vol. 31 No. 2 (2026) · hlm. 72–84

DOI
10.22146/ijbiotech.114332
ISSN
2089-2241, 0853-8654
Terbit
2026-06-30
Penerbit
Universitas Gadjah Mada
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-sa/4.0

Abstrak

Breast cancer stem cells (bCSCs) exhibit high plasticity, therapeutic resistance and immune evasion, making them critical targets for effective cancer immunotherapy. Pentagamavunone-1 (PGV-1), a curcumin analog, and its derivative, Chemoprevention Curcumin Analog-1.1 (CCA-1.1), possess cytotoxic and reactive oxygen species (ROS)-modulating properties. However, their potential role in modulating immune-related phenotypes in bCSCs remains unclear. In the study, bCSCs derived from the MDA-MB-231 cell line were treated with PGV-1 or CCA-1.1 to evaluate cytotoxicity, apoptosis, cell cycle distribution, stemness-associated markers and immune checkpoint expression. Cell viability was assessed using the CCK-8 assay. Apoptotic, stemness and immune-checkpoint profiles were analyzed using flow cytometry. PGV-1 exhibited stronger cytotoxicity against bCSCs than CCA-1.1, characterized by lower IC50 values (10.70 and 28.78 µM for PGV-1 and CCA-1.1 respectively at 24 h) and greater induction of apoptosis in a dose-dependent manner. Both compounds at concentrations of 2.67 and 7.19 µM significantly (p < 0.001) induced G2/M cell cycle arrest and reduced the CD44+CD24– stem-like population, indicating loss of stemness and enhanced differentiation. Importantly, PGV-1 significantly downregulated PD-L1 while upregulating CD80, suggesting a shift toward immunophenotypic alterations associated with a potentially more immunogenic profile. These dual effects of cytotoxic and preliminary immunophenotypic modulation highlight the ability of PGV-1 to overcome immune resistance in bCSCs. Further investigation using immune cell–based functional assays or in vivo models is required to validate whether the observed immunophenotypic modulation translates into functional immune activation and to assess the potential of PGV-1 in a co-immunotherapy setting.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 131 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • Universitas Halu Oleo
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Edy MeiyantoAfiliasi tidak diketahui25
Ratna Asmah SusidartiAfiliasi tidak diketahui8
Nurul HidayahAfiliasi tidak diketahui7
Sri HandayaniUniversity of Brawijaya6
Titiek SumarawatiAfiliasi tidak diketahui6
Rohmad Yudi UtomoAfiliasi tidak diketahui6
Adam HermawanAfiliasi tidak diketahui5
Nur Dina AmalinaAfiliasi tidak diketahui4
Ummi Maryam ZulfinAfiliasi tidak diketahui4
Annisa NovarinaAfiliasi tidak diketahui3
Dyaningtyas Dewi Pamungkas PutriAfiliasi tidak diketahui3
Adi Muradi MuharAfiliasi tidak diketahui3
Salma Yasmine AzzaharaAfiliasi tidak diketahui3
Ratih Kurnia WardaniAfiliasi tidak diketahui3
Sri Priyantini MulyaniAfiliasi tidak diketahui2
Sugeng IbrahimAfiliasi tidak diketahui2
Chodijah ChodijahAfiliasi tidak diketahui2
Zalinar UdinAfiliasi tidak diketahui2
Yogi ErtantoAfiliasi tidak diketahui2
Bayu Tirta DirjaAfiliasi tidak diketahui2
Laili Nailul MunaAfiliasi tidak diketahui2
Laeli MuntafiahAfiliasi tidak diketahui2
Bani Adlina ShabrinaAfiliasi tidak diketahui2
Rumiyati RumiyatiAfiliasi tidak diketahui2
Argandita MeiftasariAfiliasi tidak diketahui2
Nanda Resa PratamaAfiliasi tidak diketahui2
Dhania NovitasariAfiliasi tidak diketahui2
Hilyatul FadliyahAfiliasi tidak diketahui2
Setyo TrisnadiAfiliasi tidak diketahui2
Prisnu TirtanirmalaAfiliasi tidak diketahui2
Devi Nisa HidayatiAfiliasi tidak diketahui2
Imroatus SholihahAfiliasi tidak diketahui2
Nurramadhani Armada SidaUniversitas Halu Oleo2
NormaidahAfiliasi tidak diketahui2
Yurista GilangAfiliasi tidak diketahui2
Mila HanifaAfiliasi tidak diketahui2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://jurnal.ugm.ac.id/ijbiotech/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Pentagamavunone-1 and its derivative, Chemoprevention Curcumin Analog-1.1, modulate PD-L1 and CD80 expression in breast cancer stem cells</dc:title>
	<dc:creator>Alif, Iffan</dc:creator>
	<dc:creator>Putra, Agung</dc:creator>
	<dc:creator>Jenie, Riris Istighfari</dc:creator>
	<dc:creator>Ikawati, Muthi'</dc:creator>
	<dc:subject xml:lang="en-US">S bCSCs; Cancer; CCA-1.1; Curcumin analog; Immune-checkpoint; PGV-1</dc:subject>
	<dc:description xml:lang="en-US">Breast cancer stem cells (bCSCs) exhibit high plasticity, therapeutic resistance and immune evasion, making them critical targets for effective cancer immunotherapy. Pentagamavunone-1 (PGV-1), a curcumin analog, and its derivative, Chemoprevention Curcumin Analog-1.1 (CCA-1.1), possess cytotoxic and reactive oxygen species (ROS)-modulating properties. However, their potential role in modulating immune-related phenotypes in bCSCs remains unclear. In the study, bCSCs derived from the MDA-MB-231 cell line were treated with PGV-1 or CCA-1.1 to evaluate cytotoxicity, apoptosis, cell cycle distribution, stemness-associated markers and immune checkpoint expression. Cell viability was assessed using the CCK-8 assay. Apoptotic, stemness and immune-checkpoint profiles were analyzed using flow cytometry. PGV-1 exhibited stronger cytotoxicity against bCSCs than CCA-1.1, characterized by lower IC50 values (10.70 and 28.78 µM for PGV-1 and CCA-1.1 respectively at 24 h) and greater induction of apoptosis in a dose-dependent manner. Both compounds at concentrations of 2.67 and 7.19 µM significantly (p &lt; 0.001) induced G2/M cell cycle arrest and reduced the CD44+CD24– stem-like population, indicating loss of stemness and enhanced differentiation. Importantly, PGV-1 significantly downregulated PD-L1 while upregulating CD80, suggesting a shift toward immunophenotypic alterations associated with a potentially more immunogenic profile. These dual effects of cytotoxic and preliminary immunophenotypic modulation highlight the ability of PGV-1 to overcome immune resistance in bCSCs. Further investigation using immune cell–based functional assays or in vivo models is required to validate whether the observed immunophenotypic modulation translates into functional immune activation and to assess the potential of PGV-1 in a co-immunotherapy setting.</dc:description>
	<dc:publisher xml:lang="en-US">Universitas Gadjah Mada</dc:publisher>
	<dc:contributor xml:lang="en-US">Stem Cell and Cancer Research (SCCR) Indonesia and Cancer Chemoprevention Research Center (CCRC), Faculty of Pharmacy, UGM</dc:contributor>
	<dc:date>2026-06-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">Original Research Articles</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journal.ugm.ac.id/ijbiotech/article/view/114332</dc:identifier>
	<dc:identifier>10.22146/ijbiotech.114332</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Biotechnology; Vol 31, No 2 (2026); 72–84</dc:source>
	<dc:source>2089-2241</dc:source>
	<dc:source>0853-8654</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/view/114332/44355</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/view/114332/44354</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/114332/42698</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/114332/42699</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/114332/42700</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2026 The Author(s)</dc:rights>
	<dc:rights xml:lang="en-US">http://creativecommons.org/licenses/by-sa/4.0</dc:rights>
</oai_dc:dc>